Niagen Bioscience (NAGE) Competitors $10.04 +0.01 (+0.10%) As of 08/26/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NAGE vs. KYMR, AMRX, XENE, VKTX, MOR, RARE, BHC, ARWR, HCM, and CRNXShould you be buying Niagen Bioscience stock or one of its competitors? The main competitors of Niagen Bioscience include Kymera Therapeutics (KYMR), Amneal Pharmaceuticals (AMRX), Xenon Pharmaceuticals (XENE), Viking Therapeutics (VKTX), MorphoSys (MOR), Ultragenyx Pharmaceutical (RARE), Bausch Health Cos (BHC), Arrowhead Pharmaceuticals (ARWR), HUTCHMED (HCM), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry. Niagen Bioscience vs. Its Competitors Kymera Therapeutics Amneal Pharmaceuticals Xenon Pharmaceuticals Viking Therapeutics MorphoSys Ultragenyx Pharmaceutical Bausch Health Cos Arrowhead Pharmaceuticals HUTCHMED Crinetics Pharmaceuticals Kymera Therapeutics (NASDAQ:KYMR) and Niagen Bioscience (NASDAQ:NAGE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation. Which has more volatility & risk, KYMR or NAGE? Kymera Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 2.12, indicating that its share price is 112% more volatile than the S&P 500. Is KYMR or NAGE more profitable? Niagen Bioscience has a net margin of 15.24% compared to Kymera Therapeutics' net margin of -616.03%. Niagen Bioscience's return on equity of 23.12% beat Kymera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kymera Therapeutics-616.03% -31.60% -27.12% Niagen Bioscience 15.24%23.12%15.53% Does the media refer more to KYMR or NAGE? In the previous week, Kymera Therapeutics had 3 more articles in the media than Niagen Bioscience. MarketBeat recorded 6 mentions for Kymera Therapeutics and 3 mentions for Niagen Bioscience. Kymera Therapeutics' average media sentiment score of 1.70 beat Niagen Bioscience's score of 0.47 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Niagen Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation and earnings, KYMR or NAGE? Niagen Bioscience has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKymera Therapeutics$47.07M66.64-$223.86M-$3.47-12.64Niagen Bioscience$99.60M8.04$8.55M$0.2147.81 Do institutionals and insiders believe in KYMR or NAGE? 15.4% of Niagen Bioscience shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by company insiders. Comparatively, 9.4% of Niagen Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts rate KYMR or NAGE? Kymera Therapeutics presently has a consensus price target of $58.76, indicating a potential upside of 33.95%. Niagen Bioscience has a consensus price target of $13.42, indicating a potential upside of 33.67%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kymera Therapeutics is more favorable than Niagen Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kymera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 3.11Niagen Bioscience 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryKymera Therapeutics beats Niagen Bioscience on 9 of the 17 factors compared between the two stocks. Get Niagen Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for NAGE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAGE vs. The Competition Export to ExcelMetricNiagen BioscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$799.92M$3.07B$5.72B$9.73BDividend YieldN/A2.26%3.95%4.07%P/E Ratio47.8120.5230.3026.09Price / Sales8.04205.79380.6987.72Price / Cash169.5744.2437.7259.08Price / Book12.558.139.936.67Net Income$8.55M-$54.08M$3.27B$265.43M7 Day Performance4.26%4.48%3.66%3.36%1 Month Performance7.73%3.64%3.83%0.39%1 Year PerformanceN/A7.34%34.11%19.43% Niagen Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAGENiagen Bioscience1.1655 of 5 stars$10.04+0.1%$13.42+33.7%N/A$799.92M$99.60M47.81120Analyst DowngradeKYMRKymera Therapeutics2.9661 of 5 stars$42.35-0.5%$59.11+39.6%-11.8%$3.03B$44.71M-12.20170Positive NewsAMRXAmneal Pharmaceuticals3.0455 of 5 stars$9.41+0.9%$11.60+23.3%+10.7%$2.96B$2.79B941.948,100Positive NewsInsider TradeXENEXenon Pharmaceuticals2.1059 of 5 stars$37.64+0.7%$53.20+41.3%-5.3%$2.90B$9.43M-10.60210Positive NewsVKTXViking Therapeutics3.9457 of 5 stars$25.69+5.5%$86.92+238.4%-60.3%$2.89BN/A-16.7920High Trading VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730Positive NewsRAREUltragenyx Pharmaceutical4.6697 of 5 stars$29.36+0.8%$81.50+177.6%-48.2%$2.83B$560.23M-5.311,294BHCBausch Health Cos4.6955 of 5 stars$7.60-2.5%$9.00+18.5%+20.2%$2.81B$9.63B29.2120,700Analyst RevisionARWRArrowhead Pharmaceuticals3.753 of 5 stars$20.20+1.7%$43.14+113.6%-14.3%$2.79B$3.55M-15.78400News CoverageHCMHUTCHMED2.6358 of 5 stars$15.88-2.0%$28.00+76.3%-9.0%$2.77B$630.20M0.001,811CRNXCrinetics Pharmaceuticals3.6401 of 5 stars$29.09-1.2%$68.86+136.7%-41.8%$2.74B$1.39M-7.08210News CoveragePositive NewsInsider Trade Related Companies and Tools Related Companies KYMR Competitors AMRX Competitors XENE Competitors VKTX Competitors MOR Competitors RARE Competitors BHC Competitors ARWR Competitors HCM Competitors CRNX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NAGE) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Niagen Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Niagen Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access